Chamber and committees

The Scottish Government published the independently produced Improving Equity of Access to Cancer Clinical Trials in Scotland report in February 2023, which includes a recommendation for the establishment of a national register for cancer clinical trials in Scotland. The Scottish Government’s Chief Scientist Office has established an Equity of Access Implementation Board, which includes clinical research expertise from NHS Scotland, to consider this and other recommendations in the report.

Data from the NHS Research Scotland Haematology Specialty Group and Cancer Research Network presented in the table below show the number of patients who have been recruited to clinical studies, including clinical trials, for non-malignant and malignant haematology conditions, respectively in each year since 2017.

The Scottish Government currently has no specific plans to provide mobility aids to medical charities operating in war zones. However, we will work with NHS Scotland and local authorities to respond to such requests from recognised partners, including WHO and UN bodies.

The Scottish Government has provided significant financial aid to humanitarian efforts in war zones in Gaza and Ukraine. We also donated a significant amount of medical supplies to Ukraine last year as part of the UK humanitarian response, coordinated by Foreign, Commonwealth and Development Office.

The Scottish Government does not hold this information. It is publicly available from Public Health Scotland on the incidence publication page for blood cancers: Leukaemias, Hodgkin lymphoma, Non-hodgkin lymphoma and multiple myeloma.

Revenues from the UK Government’s Building Safety Levy in England will be small in relation to UK GDP and so the Levy is not expected to have any significant macroeconomic impact. As set out in the 2023-24 Programme for Government, the Scottish Government intends for a devolved Building Safety Levy to apply in equivalence to the Levy that is being introduced in England and so it does not expect the macroeconomic impact to be materially different in Scotland.

This is a matter for NHS National Services Scotland National Services Division. The information requested is not held centrally.

The Scottish Government currently has no plans to introduce such a register. We are working with Local Authorities, Health Boards and other public sector partners to understand the extent to which RAAC is present in buildings and any actions necessary in response.

The Scottish Medicines Consortium accepted tisagenlecleucel (Kymriah ® ) for routine use in NHS Scotland in February 2019 for the treatment of B-cell acute lymphoblastic leukaemia, which is a very rare type of cancer of the white blood cells.

It is used to treat children and adults under 25 years-old, where the cancer has not responded to treatment (refractory); has come back after a transplant (relapsed); or has come back after treatment for the second time. National Services Division does not currently commission a paediatric CAR-T service in Scotland, but all eligible children and young people under 16 years of age have access via referral to a specialist unit in England.

The primary objective of a devolved Building Safety Levy is to raise revenue to support the funding of cladding remediation for multi residential properties where cladding may present a risk to life. This will also ensure that homeowners and residents do not have to meet those significant costs themselves, directly.

The Scottish Government will balance this objective with minimising the impact on housing supply. We will also work with stakeholders and across the public sector to understand the cumulative impact of existing costs and regulations on the residential property and construction sectors.

The Scottish Cancer Registry does not capture whether a cancer was detected following presentation at an Accident & Emergency (A&E) department. The details in the Scottish Cancer Registry and the lack of clinical information included in the A&E attendance data leaves the relationship between cancer diagnosis and A&E attendance uncertain.

Public Health Scotland completed a study to describe emergency and non-emergency routes to cancer diagnosis in the first two years of the COVID-19 pandemic. A decision on whether to include an expanded list of cancers in the emergency vs. non-emergency routes to cancer diagnosis reporting will be made ahead of a planned publication in March 2024. However, this would be using the emergency/non-emergency definitions and so presentation at A&E would not specifically be defined as a route to diagnosis.